The association of the metabolic syndrome with target organ damage: focus on the heart, brain, and central arteries

References

• Piepoli MF, Hoes AW, Agewall S, et al. ESC scientific document group. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR). Eur Heart J. 2016;37:2315–2381.
   PubMed Web of Science ®Google Scholar
• Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987–1003.
   PubMed Web of Science ®Google Scholar
• Vinjé S, Stroes E, Nieuwdorp M, et al. The gut microbiome as novel cardio-metabolic target: the time has come! Eur Heart J. 2014;35(14):883–887.
   PubMed Web of Science ®Google Scholar
• Willi C, Bodenmann P, Ghali WA, et al. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2007;298(22):2654–2664.
   PubMed Web of Science ®Google Scholar
• Reitsma MB, Fullman N, Ng M, GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990-2015: a systematic analysis from the global burden of disease study 2015. Lancet. 2017;389(10082):1885–1906.
   PubMed Web of Science ®Google Scholar
• Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2005;48(9):1684–1699.
   PubMed Web of Science ®Google Scholar
• Egeland GM, Igland J, Vollset SE, et al. High population attributable fractions of myocardial infarction associated with waist-hip ratio. Obesity. (Silver Spring). 2016;24(5):1162–1169.
   PubMed Web of Science ®Google Scholar
• Bastien M, Poirier P, Lemieux I, et al. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis. 2014;56(4):369–381.
   PubMed Web of Science ®Google Scholar
• Maresca F, Di Palma V, Bevilacqua M, et al. Adipokines, vascular wall, and cardiovascular disease: a focused overview of the role of adipokines in the pathophysiology of cardiovascular disease. Angiology. 2015;66(1):8–24.
   PubMed Web of Science ®Google Scholar
• Després JP, Lemieux I, Bergeron J, et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol. 2008;28(6):1039–1049.
   PubMed Web of Science ®Google Scholar
• Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11(1):11–18.
   PubMed Web of Science ®Google Scholar
• Sun Z. Aging, arterial stiffness, and hypertension. Hypertension. 2015;65(2):252–256.
   PubMed Web of Science ®Google Scholar
• Ying W, Lee YS, Dong Y, et al. Expansion of islet-resident macrophages leads to inflammation affecting β cell proliferation and function in obesity. Cell Metab. 2019 Feb 5;29(2):457–474.e5.
   PubMed Web of Science ®Google Scholar
• Egeland GM, Igland J, Sulo G, et al. Non-fasting triglycerides predict incident acute myocardial infarction among those with favourable HDL-cholesterol: cohort Norway. Eur J Prev Cardiol. 2015;22(7):872–881.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;366(9497):1640–1649.
   PubMed Web of Science ®Google Scholar
• Cerhan JR, Moore SC, Jacobs EJ, et al. A pooled analysis of waist circumference and mortality in 650,000 adults. Mayo Clin Proc. 2014;89(3):335–345.
   PubMed Web of Science ®Google Scholar
• Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–2222.
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323.
   PubMed Web of Science ®Google Scholar
• Izzo R, de Simone G, Trimarco V, et al. Hypertensive target organ damage predicts incident diabetes mellitus. Eur Heart J. 2013;34(44):3419–3426.
   PubMed Web of Science ®Google Scholar
• de Simone G, Wang W, Best LG, et al. Target organ damage and incident type 2 diabetes mellitus: the Strong Heart Study. Cardiovasc Diabetol. 2017;16(1):64.
   PubMedGoogle Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10): 1953–2041.
   PubMed Web of Science ®Google Scholar
• Bestehorn K, Smolka W, Pittrow D, et al. Atherogenic dyslipidemia as evidenced by the lipid triad: prevalence and associated risk in statin-treated patients in ambulatory care. Curr Med Res Opin. 2010;26(12):2833–2839.
   PubMed Web of Science ®Google Scholar
• Lawler PR, Rosenson RS, Ko DT. Triglyceride reduction in secondary atherosclerotic cardiovascular disease prevention: core concepts in contemporary therapeutic targeting. Eur Heart J. 2020;41(15):1521–1522.
   PubMed Web of Science ®Google Scholar
• Kylin E. Studien ueber das hypertonie-hyperglyka¨ miehyperurika ¨ mie syndrom. 1923;44:105–127. Zentralblatt fuer Innere Medizin.
   Google Scholar
• Vague J. La diffe´renciation sexuelle; facteur de´terminant des formes de l’obe´ site´. Presse Med. 1947;55:339.
   PubMed Web of Science ®Google Scholar
• Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37(12):1596–1607.
   Google Scholar
• Kaplan NM. The deadly quartet and the insulin resistance syndrome: an historical overview. Hypertens Res. 1996;19(Suppl. 1):S9–S11.
   PubMedGoogle Scholar
• Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation. Diabet Med. 1998;15(7):539–553.
   PubMed Web of Science ®Google Scholar
• Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA. 2001;285(19):2486–2497.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR, et al. American Heart Association; National Heart, Lung, and Blood Institute. diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112(17):2735–2752.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–1645.
   PubMed Web of Science ®Google Scholar
• Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among US adults: NHANES III to NHANES 1999-2006. Diabetes Care. 2011;34(1):216–219.
   PubMed Web of Science ®Google Scholar
• Beltrán-Sánchez H, Harhay MO, Harhay MM, et al. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010. J Am Coll Cardiol. 2013;62(8):697–703.
   PubMed Web of Science ®Google Scholar
• Engin A. The definition and prevalence of obesity and metabolic syndrome. Adv Exp Med Biol. 2017;960:1–17.
   PubMed Web of Science ®Google Scholar
• Aguilar M, Bhuket T, Torres S, et al. Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA. 2015;313(19):1973–1974.
   PubMed Web of Science ®Google Scholar
• Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288(21):2709–2716.
   PubMed Web of Science ®Google Scholar
• Scuteri A, Najjar SS, Morrell CH, et al. Cardiovascular Health Study. The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the cardiovascular health study. Diabetes Care. 2005;28(4):882–887.
   PubMed Web of Science ®Google Scholar
• Arenillas JF, Moro MA, Dávalos A. The metabolic syndrome and stroke: potential treatment approaches. Stroke. 2007;38(7):2196–2203.
   PubMed Web of Science ®Google Scholar
• Linde A, Gerdts E, Waje-Andreassen U, et al. Covariables and types of abnormal left ventricular geometry in nonelderly ischemic stroke survivors: the Norwegian Stroke in the Young Study. J Hypertens. 2018;36(9):1858–1864.
   PubMed Web of Science ®Google Scholar
• Regitz-Zagrosek V, Lehmkuhl E, Mahmoodzadeh S. Gender aspects of the role of the metabolic syndrome as a risk factor for cardiovascular disease. Gend Med. 2007;4(Suppl):B:S162-77.
   PubMedGoogle Scholar
• Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology. 2003;144(6):2195–2200.
   PubMed Web of Science ®Google Scholar
• de Las Fuentes L, Brown AL, Mathews SJ, et al. Metabolic syndrome is associated with abnormal left ventricular diastolic function independent of left ventricular mass. Eur Heart J. 2007;28(5):553–559.
   PubMed Web of Science ®Google Scholar
• Aijaz B, Ammar KA, Lopez-Jimenez F, et al. Abnormal cardiac structure and function in the metabolic syndrome: a population-based study. Mayo Clin Proc. 2008;83(12):1350–1357.
   PubMed Web of Science ®Google Scholar
• Voulgari C, Moyssakis I, Papazafiropoulou A, et al. The impact of metabolic syndrome on left ventricular myocardial performance. Diabetes Metab Res Rev. 2010;26(2):121–127.
   PubMed Web of Science ®Google Scholar
• Sciarretta S, Ferrucci A, Ciavarella GM, et al. Markers of inflammation and fibrosis are related to cardiovascular damage in hypertensive patients with metabolic syndrome. Am J Hypertens. 2007;20(7):784–791.
   PubMed Web of Science ®Google Scholar
• Watts GF, Marwick TH. Ventricular dysfunction in early diabetic heart disease: detection, mechanisms and significance. Clin Sci (Lond). 2003;105(5):537–540.
   PubMed Web of Science ®Google Scholar
• Grassi G, Seravalle G, Mancia G. Sympathetic activation in cardiovascular disease: evidence, clinical impact and therapeutic implications. Eur J Clin Invest. 2015;45(12):1367–1375.
   PubMed Web of Science ®Google Scholar
• Knuuti J, Wijns W, Saraste A, et al. ESC scientific document group. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407–477.
   PubMed Web of Science ®Google Scholar
• Murthy VL, Naya M, Foster CR, et al. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. Circulation. 2012;126(15):1858–1868.
   PubMed Web of Science ®Google Scholar
• Jekell A, Nilsson PM, Kahan T. Treatment of hypertensive left ventricular hypertrophy. Curr Pharm Des. 2018;24(37):4391–4396.
   PubMed Web of Science ®Google Scholar
• Kosmala W, Sanders P, Marwick TH. Subclinical myocardial impairment in metabolic diseases. JACC Cardiovasc Imaging. 2017;10(6):692–703.
   PubMedGoogle Scholar
• Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27(21):2588–2605.
   PubMed Web of Science ®Google Scholar
• Scuteri A, Najjar SS, Orru’ M, et al. The central arterial burden of the metabolic syndrome is similar in men and women: the SardiNIA Study. Eur Heart J. 2010;31(5):602–613.
   PubMed Web of Science ®Google Scholar
• Topouchian J, Labat C, Gautier S, et al. Effects of metabolic syndrome on arterial function in different age groups: the advanced approach to arterial stiffness study. J Hypertens. 2018;36(4):824–833.
   PubMed Web of Science ®Google Scholar
• Nilsson PM, Laurent S, Cunha PG, et al. Metabolic syndrome, arteries research (MARE) consortium. Characteristics of healthy vascular ageing in pooled population-based cohort studies: the global metabolic syndrome and artery research consortium. J Hypertens. 2018;36(12):2340–2349.
   PubMed Web of Science ®Google Scholar
• Scuteri A, Najjar SS, Muller DC, et al. Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. J Am Coll Cardiol. 2004;43(8):1388–1395.
   PubMed Web of Science ®Google Scholar
• Saeed S, Waje-Andreassen U, Fromm A, et al. Early vascular aging in young and middle-aged ischemic stroke patients: the Norwegian stroke in the young study. PLoS One. 2014 Nov 18;9(11):e112814.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109(5):594–600.
   PubMed Web of Science ®Google Scholar
• Magnusson M, Jujic A, Hedblad B, et al. Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective malmo diet and cancer study. J Clin Endocrinol Metab. 2012;97(2):638–645.
   PubMed Web of Science ®Google Scholar
• Olsen MH, Hansen TW, Christensen MK, et al. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension. 2005;46(4):660–666.
   PubMed Web of Science ®Google Scholar
• Yang S, Huang S, Daniels LB, et al. NT-proBNP, race and endothelial function in the Multi-ethnic study of atherosclerosis. Heart. 2019;105(20):1590–1596.
   PubMed Web of Science ®Google Scholar
• Marwick TH, Gillebert TC, Aurigemma G, et al. Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). J Am Soc Echocardiogr. 2015;28(7):727–754.
   PubMed Web of Science ®Google Scholar
• From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol. 2010;55(4):300–305.
   PubMed Web of Science ®Google Scholar
• Ernande L, Audureau E, Jellis CL, et al. Clinical implications of echocardiographic phenotypes of patients with diabetes mellitus. J Am Coll Cardiol. 2017;70(14):1704–1716.
   PubMed Web of Science ®Google Scholar
• Ng AC, Delgado V, Bertini M, et al. Findings from left ventricular strain and strain rate imaging in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol. 2009;104(10):1398–1401.
   PubMed Web of Science ®Google Scholar
• Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1): 1–39.
   PubMed Web of Science ®Google Scholar
• de Simone G, Izzo R, Chinali M, et al. Does information on systolic and diastolic function improve prediction of a cardiovascular event by left ventricular hypertrophy in arterial hypertension? Hypertension. 2010;56(1):99–104.
   PubMed Web of Science ®Google Scholar
• de Simone G, Mancusi C, Izzo R, et al. Obesity and hypertensive heart disease: focus on body composition and sex differences. Diabetol Metab Syndr. 2016;8(1):79.
   PubMedGoogle Scholar
• Cuspidi C, Giudici V, Meani S, et al. Extracardiac organ damage in essential hypertensives with left ventricular concentric remodelling. J Hum Hypertens. 2010;24(6):380–386.
   PubMed Web of Science ®Google Scholar
• Rider OJ, Nethononda R, Petersen SE, et al. Concentric left ventricular remodeling and aortic stiffness: a comparison of obesity and hypertension. Int J Cardiol. 2013;167(6):2989–2994.
   PubMed Web of Science ®Google Scholar
• Shah RV, Abbasi SA, Heydari B, et al. Insulin resistance, subclinical left ventricular remodeling, and the obesity paradox: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2013;61(16):1698–1706.
   PubMed Web of Science ®Google Scholar
• de Simone G, Devereux RB, Chinali M, et al. Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: the Strong Heart Study. Nutr Metab Cardiovasc Dis. 2009;19(2):98–104.
   PubMed Web of Science ®Google Scholar
• Lønnebakken MT, Izzo R, Mancusi C, et al. Left ventricular hypertrophy regression during antihypertensive treatment in an outpatient clinic (the campania salute network). J Am Heart Assoc. 2017;6(3):pii: e004152.
   PubMed Web of Science ®Google Scholar
• Lønnebakken MT, Mancusi C, Losi MA, et al. Weight loss facilitates reduction of left ventricular mass in obese hypertensive patients: the campania salute network. Nutr Metab Cardiovasc Dis. 2019;29(2):185–190.
   PubMed Web of Science ®Google Scholar
• Ambale Venkatesh B, Volpe GJ, Donekal S, et al. Association of longitudinal changes in left ventricular structure and function with myocardial fibrosis: the multi-ethnic study of atherosclerosis study. Hypertension. 2014;64(3):508–515.
   PubMed Web of Science ®Google Scholar
• Plaksej R, Kosmala W, Frantz S, et al. Relation of circulating markers of fibrosis and progression of left and right ventricular dysfunction in hypertensive patients with heart failure. J Hypertens. 2009;27(12):2483–2491.
   PubMed Web of Science ®Google Scholar
• Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and reninangiotensin-aldosterone system. Circulation. 1991;83:1849–1865.
   PubMed Web of Science ®Google Scholar
• Tadic M, Cuspidi C, Calicchio F, et al. Diabetic cardiomyopathy: how can cardiac magnetic resonance help? Acta Diabetol. 2020 Apr 13. DOI:https://doi.org/10.1007/s00592-020-01528-2.
   Google Scholar
• Kosmala W, Przewlocka-Kosmala M, Wojnalowicz A, et al. Integrated backscatter as a fibrosis marker in the metabolic syndrome: association with biochemical evidence of fibrosis and left ventricular dysfunction. Eur Heart J Cardiovasc Imaging. 2012;13(6):459–467.
   PubMed Web of Science ®Google Scholar
• Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, et al. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome. JACC Cardiovasc Imaging. 2011;4(12):1239–1249.
   PubMed Web of Science ®Google Scholar
• Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, et al. Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade. Heart. 2013;99(5):320–326.
   PubMed Web of Science ®Google Scholar
• Poulsen SH, Andersen NH, Ivarsen PI, et al. Doppler tissue imaging reveals systolic dysfunction in patients with hypertension and apparent ‘isolated’ diastolic dysfunction. J Am Soc Echocardiogr. 2003;16(7):724–731.
   PubMed Web of Science ®Google Scholar
• Rosen BD, Saad MF, Shea S, et al. Hypertension and smoking are associated with reduced regional left ventricular function in asymptomatic: individuals the multi-ethnic study of atherosclerosis. J Am Coll Cardiol. 2006;47(6):1150–1158.
   PubMed Web of Science ®Google Scholar
• Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction. Heart. 2014;100(21):1673–1680.
   PubMed Web of Science ®Google Scholar
• Saito M, Khan F, Stoklosa T, et al. Prognostic implications of LV strain risk score in asymptomatic patients with hypertensive heart disease. JACC Cardiovasc Imaging. 2016;9(8):911–921.
   PubMed Web of Science ®Google Scholar
• Ng ACT, Strudwick M, van der Geest RJ, et al. Impact of epicardial adipose tissue, left ventricular myocardial fat content, and interstitial fibrosis on myocardial contractile function. Circ Cardiovasc Imaging. 2018;11(8):e007372.
   PubMed Web of Science ®Google Scholar
• Selvaraj S, Martinez EE, Aguilar FG, et al. Association of central adiposity with adverse cardiac mechanics: findings from the hypertension genetic epidemiology network study. Circ Cardiovasc Imaging. 2016;9(6):6.
   Web of Science ®Google Scholar
• Khan SS, Shah S, Colangelo L, et al. Association of patterns of change in adiposity with diastolic function and systolic myocardial mechanics from early adulthood to middle age: the coronary artery risk development in young adults study. J Am Soc Echocardiogr. 2018;31(12):1261–1269.
   PubMed Web of Science ®Google Scholar
• Senni M, Paulus WJ, Gavazzi A, et al. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J. 2014;35(40):2797–2815.
   PubMed Web of Science ®Google Scholar
• Einarsen E, Gerdts E, Waje-Andreassen U, et al. Association of increased arterial stiffness with diastolic dysfunction in ischemic stroke patients: the Norwegian Stroke in the Young Study. J Hypertens. 2020;38(3):467–473.
   PubMed Web of Science ®Google Scholar
• Kosmala W, Przewlocka-Kosmala M, Rojek A, et al. Association of abnormal left ventricular functional reserve with outcome in heart failure with preserved ejection fraction. JACC Cardiovasc Imaging. 2018;11(12):1737–1746.
   PubMed Web of Science ®Google Scholar
• Obokata M, Reddy YNV, Pislaru SV, et al. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017;136(1):6–19.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, D’Agostino RB, Belanger AJ, et al. Left atrial size and the risk of stroke and death. The Framingham heart study. Circulation. 1995;92(4):835–841.
   PubMed Web of Science ®Google Scholar
• Cuspidi C, Meani S, Fusi V, et al. Prevalence and correlates of left atrial enlargement in essential hypertension: role of ventricular geometry and the metabolic syndrome: the evaluation of target organ damage in hypertension study. J Hypertens. 2005;23(4):875–882.
   PubMed Web of Science ®Google Scholar
• Saeed S, Gerdts E. Incremental prognostic value of left atrial function indices in the prediction of incident atrial fibrillation in patients with ST-elevation myocardial infarction. Int J Cardiol. 2018;263:7–8.
   PubMed Web of Science ®Google Scholar
• Wong CX, Sullivan T, Sun MT, et al. Obesity and the risk of incident, post-operative, and post-ablation atrial fibrillation: a meta-analysis of 626,603 individuals in 51 studies. J Am Coll Cardiol Clin Electrophysiol. 2015;1:139–152.
   Google Scholar
• Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev. 2004;25(4):543–567.
   PubMed Web of Science ®Google Scholar
• Seferović PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J. 2015;36(27):1718–1727. 1727a–1727c.
   PubMed Web of Science ®Google Scholar
• Peterson LR, Gropler RJ. Radionuclide imaging of myocardial metabolism. Circ Cardiovasc Imaging. 2010;3(2):211–222.
   PubMed Web of Science ®Google Scholar
• Rijzewijk LJ, van der Meer RW, Lamb HJ, et al. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol. 2009;54(16):1524–1532.
   PubMed Web of Science ®Google Scholar
• Mancusi C, Losi MA, Izzo R, et al. Effect of diabetes and metabolic syndrome on myocardial mechano-energetic efficiency in hypertensive patients. The campania salute network. J Hum Hypertens. 2017;31(6):395–399.
   PubMed Web of Science ®Google Scholar
• Kahn R, Buse J, Ferrannini E, et al. American diabetes association; European association for the study of diabetes.The metabolic syndrome: time for a critical appraisal. Diabetes Care. 2005;28(9):2289–2304.
   PubMed Web of Science ®Google Scholar
• Nilsson PM, Tuomilehto J, Rydén L. The metabolic syndrome – what is it and how should it be managed? Eur J Prev Cardiol. 2019;26(2_suppl):33–46.
   PubMed Web of Science ®Google Scholar
• Sjögren M, Lyssenko V, Jonsson A, et al. The search for putative unifying genetic factors for components of the metabolic syndrome. Diabetologia. 2008;51(12):2242–2251.
   PubMed Web of Science ®Google Scholar
• Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110(10):1245–1250.
   PubMed Web of Science ®Google Scholar
• Mente A, Yusuf S, Islam S, et al. INTERHEART Investigators. Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 countries. J Am Coll Cardiol. 2010;55(21):2390–2398.
   PubMed Web of Science ®Google Scholar
• Hughes K, Yeo PP, Lun KC, et al. Cardiovascular diseases in Chinese, Malays, and Indians in Singapore. II. Differences in risk factor levels. J Epidemiol Community Health. 1990;44(1):29–35.
   PubMed Web of Science ®Google Scholar
• Ferro JM, Massaro AR, Mas JL. Aetiological diagnosis of ischaemic stroke in young adults. Lancet Neurol. 2010;9(11):1085–1096.
   PubMed Web of Science ®Google Scholar
• Fromm A, ØA H, Naess H, et al. Atherosclerosis in trial of org 10172 in acute stroke treatment subtypes among young and middle-aged stroke patients: the Norwegian stroke in the young study. J Stroke Cerebrovasc Dis. 2016;25(4):825–830.
   PubMed Web of Science ®Google Scholar
• Fromm A, Haaland ØA, Naess H, et al. Risk factors and their impact on carotid intima-media thickness in young and middle-aged ischemic stroke patients and controls: the Norwegian stroke in the young study. BMC Res Notes. 2014;7(1):176.
   PubMedGoogle Scholar
• Stewart LK, Kline JA. Metabolic syndrome increases risk of venous thromboembolism recurrence after acute pulmonary embolism. Ann Am Thorac Soc. 2020;17(7):821–828.
   PubMed Web of Science ®Google Scholar
• Stewart LK, Beam DM, Casciani T, et al. Effect of metabolic syndrome on mean pulmonary arterial pressures in patients with acute pulmonary embolism treated with catheter-directed thrombolysis. Int J Cardiol. 2020;302:138–142.
   PubMed Web of Science ®Google Scholar
• Li X, Li X, Lin H, et al. Metabolic syndrome and stroke: a meta-analysis of prospective cohort studies. J Clin Neurosci. 2017;40:34–38.
   PubMed Web of Science ®Google Scholar
• Saeed S, Gerdts E, Waje-Andreassen U, et al. Left ventricular myocardial dysfunction in young and middle-aged ischemic stroke patients: the Norwegian stroke in the young study. J Hypertens. 2019;37(3):538–545.
   PubMed Web of Science ®Google Scholar
• Kim B, Feldman EL. Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. Exp Mol Med. 2015;47(3):e149.
   PubMedGoogle Scholar
• Raffaitin C, Gin H, Empana JP, et al. Metabolic syndrome and risk for incident Alzheimer’s disease or vascular dementia: the three-city study. Diabetes Care. 2009;32(1):169–174.
   PubMed Web of Science ®Google Scholar
• Kalmijn S, Foley D, White L, et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men: the Honolulu-Asia aging study. Arterioscler Thromb Vasc Biol. 2000;20(10):2255–2260.
   PubMed Web of Science ®Google Scholar
• Perlmuter LC, Nathan DM, Goldfinger SH, et al. Triglyceride levels affect cognitive function in noninsulin-dependent diabetics. J Diabet Complications. 1988;2(4):210–213.
   PubMedGoogle Scholar
• Marfella R, Paolisso G. Increased arterial stiffness trumps on blood pressure in predicting cognitive decline in low-risk populations. Hypertension. 2016;67(1):30–31.
   PubMed Web of Science ®Google Scholar
• Triantafyllidi H, Trivilou P, Ikonomidis I, et al. Is arterial hypertension control enough to improve aortic stiffness in untreated patients with hypertension? A 3-year follow-up study. Angiology. 2015;66(8):759–765.
   PubMed Web of Science ®Google Scholar
• Boutouyrie P, Lacolley P, Briet M, et al. Pharmacological modulation of arterial stiffness. Drugs. 2011;71(13):1689–1701.
   PubMed Web of Science ®Google Scholar
• Ong KT, Delerme S, Pannier B, et al. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients. J Hypertens. 2011;29(6):1034–1042.
   PubMed Web of Science ®Google Scholar
• Mitchell GF, Dunlap ME, Warnica W, et al. Prevention of events with angiotensin-converting enzyme inhibition investigators. Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy. Hypertension. 2007;49(6):1271–1277.
   PubMed Web of Science ®Google Scholar
• Laurent S, Boutouyrie P. Vascular mechanism collaboration. dose-dependent arterial destiffening and inward remodeling after olmesartan in hypertensives with metabolic syndrome. Hypertension. 2014;64(4):709–716.
   PubMed Web of Science ®Google Scholar
• Orr JS, Dengo AL, Rivero JM, et al. Arterial destiffening with atorvastatin in overweight and obese middle-aged and older adults. Hypertension. 2009;54(4):763–768.
   PubMed Web of Science ®Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes prevention program research group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.
   PubMed Web of Science ®Google Scholar
• López-Jaramillo P, Barbosa E, Molina DI, et al. Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome. J Hypertens. 2019;37(6):1126–1147.
   PubMed Web of Science ®Google Scholar
• Ayers K, Byrne LM, DeMatteo A, et al. Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension. 2012;59(4):893–898.
   PubMed Web of Science ®Google Scholar
• Aizawa K, Shoemaker JK, Overend TJ, et al. Effects of lifestyle modification on central artery stiffness in metabolic syndrome subjects with pre-hypertension and/or pre-diabetes. Diabetes Res Clin Pract. 2009;83(2):249–256.
   PubMed Web of Science ®Google Scholar
• Goldberg Y, Boaz M, Matas Z, et al. Weight loss induced by nutritional and exercise intervention decreases arterial stiffness in obese subjects. Clin Nutr. 2009;28(1):21–25.
   PubMed Web of Science ®Google Scholar
• Patino-Alonso MC, Recio-Rodríguez JI, Belio JF, et al. EVIDENT group. Factors associated with adherence to the Mediterranean diet in the adult population. J Acad Nutr Diet. 2014;114(4):583–589.
   PubMed Web of Science ®Google Scholar
• Alpert MA, Agrawal H, Aggarwal K, et al. Heart failure and obesity in adults: pathophysiology, clinical manifestations and management. Curr Heart Fail Rep. 2014;11(2):156–165.
   PubMedGoogle Scholar
• Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–967.
   PubMed Web of Science ®Google Scholar
• Saliba LJ, Maffett S. Hypertensive heart disease and obesity: a review. Heart Fail Clin. 2019;15(4):509–517.
   PubMed Web of Science ®Google Scholar